1. Atwell, G. J., Boyd, M., Palmer, B. D., Anderson, R. F, Pullen, S. M., Wilson, W. R., and Denny, W. A., 1996, Synthesis and evaluation of 4-substituted analogues of 5-[N-N-bis(2-chloroethyl)amino]-2-nitrobenzamide as bioreductively activated prodrugs using an Escherichia coli nitroreductase, Anticancer Drug Des. 11:553–567.
2. Azoulay, M., Florent, J-C., Monneret, C., Gesson, J. P., Jacquesy, J-C., Tillequin, F, Koch, M., Bosslet, K., Czech, J., and Hoffman, D., 1995, Prodrugs of anthracycline antibiotics suited for tumour-specific activation, Anticancer Drug Des. 10:441–450.
3. Bagshawe, K. D., 1987, Antibody directed enzymes revive anti-cancer prodrugs concept, Br. J. Cancer 56:531–532.
4. Bagshawe, K. D., Springer, C. J., Searle, F., Antoniw, P., Sharma, S. K., Melton, R. G., and Sherwood, R. F., 1988, A cytotoxic agent can be generated selectively at cancer sites, Br. J. Cancer 58: 700–703.
5. Bagshawe, K. D., Sharma, S. K., Springer, C. J., and Antoniw, P., 1995, Antibody-directed enzyme prodrug therapy: A pilot scale clinical trial, Tumor Targeting 1:17–29.